Peroxisome proliferator-activated receptor gamma expression in urothelial carcinomas of the bladder: Association with differentiation, proliferation and clinical outcome

European Journal of Surgical Oncology

Volumn 35, Issue 2, 2009, Pages 197-201

  Mylona, E ^a   Giannopoulou, I ^a   Diamantopoulou, K ^a   Bakarakos, P ^a   Nomikos, A ^a   Zervas, A ^b   Nakopoulou, L ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Bladder urothelial carcinoma; Immunohistochemistry; Ki 67; PPAR ; Prognosis

Indexed keywords

KI 67 ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CELL NUCLEUS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UROTHELIAL BLADDER CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PPAR GAMMA; PROGNOSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 58249122674     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.04.003     Document Type: Article

References (25)

1. In: Eble J.N., Souter G., Epstein J.I., and Sesterhenn I.A. (Eds). Tumors of the urinary system and male genital organs, World Health Organization Classification of tumors Pathology and Genetics (2004), IARC Press, Lyon
2. Blanquart C., Barbier O., Fruchart J.C., Staels B., and Glineur C. Persoxisome proliferators-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 85 (2003) 267-273
3. Jain S., Pulikuri S., Zhu Y., et al. Differential expression of the peroxisome proliferators-activated receptors γ (PPARγ) and the coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon and breast of the mouse. Am J Pathol 153 (1998) 349-354
4. Rosen E.D., Sarraf P., Troy A.E., et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4 (1999) 611-617
5. Vamecq J., and Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 354 (1999) 141-148
6. Saltiel A.R., and Olefsky J.M. Thiazolidinediones in the treatment of isulin resistance and type II diabetes. Diabetes 45 (1996) 1661-1669
7. Nwankwo J.O., and Robbins M.E. Peroxisome proliferators-activated receptor-gamma expression in human malignant and normal brain, breast and prostate-derived cell. Prostaglandins Leukotrienes Essent Fatty Acids 64 4-5 (2001) 241-245
8. Chang T.H., and Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 60 (2000) 1129-1138
9. Elnemr A., Ohta T., Iwata K., et al. PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int J Oncol 17 (2000) 1157-1164
10. Kawa S., Nikaido T., Unno H., Usuda N., Nakayama K., and Kiyosawa K. Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas 24 (2002) 1-7
11. Mueller E., Sarraf P., Tontonoz P., et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1 (1998) 465-470
12. Fournier T., Handschuh K., Tsatsaris Y., and Evain-Brion D. Involvement of PPARgamma in human trophoblast invasion. Placenta 28 (2007) S76-S81
13. Sawai H., Liu J., Reber H.A., Hines O.J., and Eibl G. Activation of peroxisome proliferator-activated receptor gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system. Mol Cancer Res 4 (2006) 159-167
14. Rumi M.A., Ishihara S., Kazumori H., Kadowaki Y., and Kinoshita Y. Can PPAR gamma ligands be used in cancer therapy?. Curr Med Chem Anticancer Agents 4 (2004) 465-477
15. Guan Y., Zhang Y., Davis L., and Breyer M.D. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 273 (1997) F1013-F1022
16. Kawakami S., Arai G., Hayashi T., et al. PPARgamma ligand suppress proliferation of human urothelial basal cells in vitro. J Cell Physiol 191 (2002) 310-319
17. Nakashiro K.I., Hayashi Y., Kita A., et al. Role of peroxisome proliferators-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol 159 (2001) 591-597
18. Yoshimura R., Motsuyama M., Segawa Y., et al. Expression of peroxisome proliferators-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 104 (2003) 597-602
19. Possati L., Rocchetti R., Talevi S., et al. The role of peroxisome proliferator-activated receptor γ in bladder cancer in relation to angiogenesis and progression. Gen Pharmacol 35 (2002) 269-275
20. Nakopoulou L., Vourlakou C., Zevas A., Tsonou A., Giakopoulou H., and Dimopoulos M.-A. The prevalence of bcl-2, p53 and Ki67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 29 (1998) 146-154
21. Pavlopoulos PM, Davaris P. Software development for the evaluation of histochemical and immunohistochemical color images. Presented at the 24th Annual Panhellenic Medical Congress. Athens, Greece, May 5-9; 1993.
22. Pavlopoulos P.M., Konstantinidou A., Agapitos E., Kavantzas N., Nikolopoulou P., and Davaris P. A morphometric study of neovascularization in colorectal carcinoma. Cancer 83 (1998) 2067-2075
23. Varley C.L., Stahlschmidt J., Wen-Chun L., et al. Pole of PPARγ and EGFR signaling in the urothelial terminal differentiation programme. J Cell Sci 117 (2004) 2029-2036
24. Guan Y.-F., Zhang Y.-H., Breyer R.M., Davis L., and Breyer D. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1 (1999) 330-339
25. Kassouf W., Chintharlapalli S., Abdelrahim M., Nelkin G., Safe S., and Kamat A.M. Inhibition of bladder tumor rowth by 1,1-bis(3′-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor γ agonists. Cancer Res 66 (2006) 412-418